The discovery of a non-coding isoform (Novel-3) suggests that promoting exon 2 skipping could serve as a strategy to lower functional APOC3 levels, with potential benefits for hypertriglyceridemia treatment. The gene discussed is APOC3; the disease is hypertriglyceridemia.